Cancer vaccine may advance melanoma outcomes
A novel vaccine could reduce the risk of recurrence- and metastasis-free survival in individuals with melanoma. There are currently more than 1.5 million people who have been diagnosed with the deadly type of skin cancer in the United States, according to a news report from Reuters.
In an interim analysis of a late-stage clinical trial, researchers analyzed the efficacy of a personalized mRNA vaccine in combination with the immunotherapy agent pembrolizumab administered in the adjuvant treatment setting among more than 1,100 high-risk patients with stage IIb or stage IV melanoma who underwent surgical resection of their tumors. The participants were randomly assigned to receive either the melanoma vaccine and up to nine doses of pembrolizumab or pembrolizumab alone.
The researchers noted that the melanoma vaccine works by training the body’s own immune cells to target and eliminate mutations specific to the cancer cells. They found that the patients who received the vaccine experienced lower rates of cancer recurrence and metastasis. However, the researchers have not yet determined the rate of overall survival following treatment with the combination therapy.
The positive outcomes of the analysis suggested that, with its breakthrough therapy designation and pending regulatory approval, patients could have access to the novel therapy by 2027. The researchers argued that the results of the trial could lay the groundwork for future improvements in the treatment of solid tumors such as lung, breast and pancreatic cancers.
Read more: Reuters
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.